

Journal Pre-proof

Therapeutic Effect of Intravenous Levetiracetam in Status Epilepticus: A meta-analysis and systematic review

Shan-shan Chu, Hai-jiao Wang, Li-Na Zhu, Da Xu, Xue-ping Wang, Ling Liu



PII: S1059-1311(19)30153-0

DOI: <https://doi.org/10.1016/j.seizure.2019.11.007>

Reference: YSEIZ 3597

To appear in: *Seizure: European Journal of Epilepsy*

Received Date: 3 March 2019

Revised Date: 15 November 2019

Accepted Date: 21 November 2019

Please cite this article as: Chu S-shan, Wang H-jiao, Zhu L-Na, Xu D, Wang X-ping, Liu L, Therapeutic Effect of Intravenous Levetiracetam in Status Epilepticus: A meta-analysis and systematic review, *Seizure: European Journal of Epilepsy* (2019), doi: <https://doi.org/10.1016/j.seizure.2019.11.007>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier.

Therapeutic Effect of Intravenous Levetiracetam in Status Epilepticus: A meta-analysis and systematic review

Shan-shan Chu^a, Hai-jiao Wang^a, Li-Na Zhu^a, Da Xu^a, Xue-ping Wang^a, Ling Liu^a

^aDepartment of Neurology, West China Hospital, Sichuan University, Wai Nan Guo Xue Lane 37#, Chengdu 610041, China

Highlights

- IV LEV appears to be as effective as PHT, VPA, and LOR for the treatment of SE.
- IV LEV as add-on therapy of CNP had no superiority in seizure cessation than CNP plus placebo.
- IV LEV may have a better tolerability profile than other AEDs do.
- More rigorous RCTs are required to determine the place of IV LEV in SE.

ABSTRACT

Purpose: We performed this analysis to evaluate the efficacy and safety of intravenous levetiracetam (IV LEV) in patients with status epilepticus.

Method: Studies were searched in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for available randomized controlled trials (RCTs) comparing the efficacy and/or safety of IV LEV with other antiepileptic drugs (AEDs). Meta-analysis was performed using the random-effects model to calculate risk ratio with the RevMan 5.3 software.

Results: Six RCTs with a total of 543 patients were included. There was no significant differences in clinical seizure cessation and hospital mortality, either between IV LEV and IV phenytoin (PHT) or between IV LEV and IV valproate (VPA). Compared with IV PHT, IV LEV had a lower risk of poor neurological outcome. For IV LEV compared with IV lorazepam (LOR), no

Download English Version:

<https://daneshyari.com/en/article/13426599>

Download Persian Version:

<https://daneshyari.com/article/13426599>

[Daneshyari.com](https://daneshyari.com)